Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Buys $6,499,984.00 in Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Global Strategic Fund Venbio purchased 382,352 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the acquisition, the insider directly owned 4,181,367 shares of the company’s stock, valued at $71,083,239. This trade represents a 10.06% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Price Performance

Shares of NASDAQ ATTO opened at $18.06 on Thursday. Attovia Therapeutics, Inc. has a 12 month low of $16.15 and a 12 month high of $22.79.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. grew its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.